UCI Beall Applied Innovation

Research Translation Group

Research Translation Group

Available Technologies

Contact Us

Request Information

Permalink

Drug Inhibition of NLRP3 Inflammasome Activation

Tech ID: 33758 / UC Case 2024-928-0

BRIEF DESCRIPTION

This technology provides a novel insight into the NLRP3 inflammasome's role in the immune response and introduces a repurposed drug that inhibits its activation.

FULL DESCRIPTION

The NLRP3 inflammasome is crucial for the innate immune response, activated by a wide range of agents. This technology explores how NLRP3 interacts with mitochondrial DNA (mtDNA), revealing that it binds non-oxidized and oxidized mtDNA with different affinities. A significant discovery is the repurposing of a drug targeting human glycosylase to inhibit NLRP3 inflammasome activation, offering a new therapeutic approach for diseases involving the inflammasome.

SUGGESTED USES

- **>>** Pharmaceuticals for treating chronic inflammatory diseases like gout, type 2 diabetes, and atherosclerosis.
- >> Therapeutic interventions for rare genetic disorders associated with NLRP3 mutations.
- >> Anti-inflammatory drugs with reduced side effects for a broad patient demographic.
- >> Research tools for studying the innate immune response and inflammation.

ADVANTAGES

- » Directly targets the molecular mechanism of NLRP3 inflammasome activation.
- » Offers a new therapeutic strategy for treating a wide range of inflammatory diseases.
- >> Potentially reduces side effects associated with current anti-inflammatory treatments.
- » Based on detailed molecular understanding, increasing the specificity of the treatment.
- >> Provides insights into the role of oxidized mtDNA in immune response activation.

PATENT STATUS

Patent Pending

RELATED MATERIALS

>> Cabral, A., Cabral, J.E., Wang, A. et al. Differential Binding of NLRP3 to non-oxidized and Ox-mtDNA mediates NLRP3 Inflammasome Activation. Commun Biol 6, 578 (2023).

CONTACT

Steven T. Huyn shuyn@uci.edu tel: 949-824-7913.



OTHER INFORMATION

CATEGORIZED AS

» Medical

Disease:Autoimmune and Inflammation

>> Therapeutics

RELATED CASES

2024-928-0

UCI Beall Applied Innovation

5270 California Avenue / Irvine, CA 92697-7700 / Tel: 949.824.2683



© 2024, The Regents of the University of California Terms of use Privacy Notice